Compare Hasbro, Inc. (HAS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Medpace Holdings Inc — how do they compare? Hasbro, Inc. trades at $92.82 (market cap $13.05B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Hasbro, Inc. pays a 3.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Medpace Holdings Inc for 14 Days on average.
| HAS | MEDP | |
|---|---|---|
Market Cap | $13.05B | $16.82B |
Volume | 1,207,655 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $630.19 |
52-Week Low | $70.95 | $393.42 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $15.24B | $16.44B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains positive with a $107.60 price target, representing 18.5% upside potential from current levels. Recent news highlights continued momentum in the Magic: The Gathering franchise and new product collaborations.
The outlook remains constructive with projected revenue growth to $5.0B in 2026 and net income recovery to $794M. Key risks include high debt levels at 59.09% debt-to-asset ratio and recent net income volatility. The stock offers value with reasonable P/E of 16.14x and strong institutional interest, though investors should monitor Q3 2026 earnings on October 20 for confirmation of the turnaround trajectory.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
